Evidence map›Paper›PMID 26677454›Full record

ArticleInternational journal of advanced research2015

In vitro and in vivo antitumor activity of gemcitabine loaded thermosensitive liposomal nanoparticles and mild hyperthermia in pancreatic cancer.

Kevin Affram, Ofonime Udofot, Anna Cat, Edward Agyare

Open access · greenAbstract read
In one paragraph

Article in International journal of advanced research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Re/Journal of medicinal chemistry · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kevin AfframDivision of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, FL, USA.
Ofonime UdofotDivision of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, FL, USA.
Anna CatDivision of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, FL, USA.
Edward AgyareDivision of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, FL, USA.
Florida Agricultural and Mechanical University · US

Funding

STEERING COMMITTEEU54MD008149 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI OFILI, ELIZABETH O. · 2012 to 2018
$21.1M
Recruitment and HiringG12MD007582 · NIMHD · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI SOLIMAN, KARAM F.A. · 2012 to 2017
$16.0M
Targeted Nanocarrier Combination Based Therapy for Lung CancerP20MD006738 · NIMHD · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI SOLIMAN, KARAM F.A. · 2012 to 2016
$5.6M
NIMHD NIH HHS G12 MD007582NIMHD NIH HHS P20 MD006738NIMHD NIH HHS U54 MD008149
6 · The paper itself

Abstract

The study was designed to explore the feasibility of increasing the delivery of gemcitabine-HCL (Gem), a poor membrane permeable and short half-life drug, through PEGylated thermosensitive liposomal nanoparticles (TSLnps) delivery system followed by mild hyperthermia (mTH) at 42°C. In vitro release pattern of Gem-TSLnps showed a significant Gem release (60%, p<0.01) at 42°C compared to that released at 37°C (29%). Cell viability and clonogenic assay demonstrated significant inhibition of MiaPaCa-2 cells growth by Gem-TSLnps + mHT compared to Gem alone. Further, IC

Indexed as

Anti-tumorGemcitabine-HCLLiposomesLiver enzymesPancreatic cancerThermosensitive

Identifiers

PMID26677454
PMCPMC4677791
OpenAlexW2204482751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.